December 18, 2000 - 6:38 p.m.
Gilead Sciences Acquires Rights To Novel Oncology Compound From Southern Research Institute
Printer Friendly Version 
December 14, 2000 - 6:18 p.m.
Gilead Sciences Announces Private Offering of Convertible Subordinated Notes
Printer Friendly Version 
December 14, 2000 - 6:14 p.m.
Tamiflu™ Granted FDA Approval for Treatment of Flu in Children
Printer Friendly Version 
December 12, 2000 - 6:14 p.m.
Roche's Oral Flu Drug Tamiflu™ Gets Approval in Japan
Printer Friendly Version 
December 11, 2000 - 6:12 p.m.
Gilead Sciences Receives Approval to Initiate Clinical Trials in China for Adefovir Dipivoxil, an Investigational Compound for the Treatment of Chronic Hepatitis B Infection
Printer Friendly Version 
December 11, 2000 - 6:08 p.m.
Gilead Sciences Initiates Private Placement of Convertible Subordinated Notes
Printer Friendly Version 
December 05, 2000 - 5:59 p.m.
Gilead Sciences Announces License Agreement for Investigational Cancer Compound with Glaxo Wellcome PLC
Printer Friendly Version 
November 20, 2000 - 5:56 p.m.
Roche's Tamiflu™ Granted FDA Approval for the Prevention of Influenza
Printer Friendly Version 
November 17, 2000 - 5:54 p.m.
Study Results Published in Journal of Clinical Infectious Diseases Demonstrate That Ambisome® Has an Improved Safety Profile Compared to Abelcet®
Printer Friendly Version 
November 09, 2000 - 5:53 p.m.
Gilead Sciences Board of Directors Approves Proposed Increase in Authorized Capital for Planned 2-for-1 Stock Split
Printer Friendly Version 
November 02, 2000 - 5:50 p.m.
Gilead Begins Phase II Study of NX 211, Investigational Compound for the Treatment of Patients with Topotecan Resistant Ovarian Cancer
Printer Friendly Version 
October 31, 2000 - 5:44 p.m.
Gilead Sciences Announces Preliminary Results from Study of Adefovir Dipivoxil 10 mg for the Treatment of Patients Co-infected with HIV and Chronic Hepatitis B
Printer Friendly Version 
October 26, 2000 - 5:35 p.m.
Gilead Sciences Announces Third Quarter 2000 Financial Results
Printer Friendly Version 
October 22, 2000 - 5:31 p.m.
Gilead Sciences Presents 48-Week Viral Resistance Data From Phase II Study of Investigational Anti-HIV Agent, Tenofovir DF
Printer Friendly Version 
September 18, 2000 - 5:27 p.m.
New Tamiflu™ Data Shows Early Treatment Optimizes Benefit for Flu Sufferers
Printer Friendly Version 
September 18, 2000 - 5:25 p.m.
Gilead Sciences Announces Results from 48-Week Study of Once-Daily Anti-HIV Agent Tenofovir DF
Printer Friendly Version 
September 17, 2000 - 5:21 p.m.
Gilead Announces Data Demonstrating that Single Dose of AmBisome® Safely and Effectively Treats Visceral Leishmaniasis in India
Printer Friendly Version 
September 17, 2000 - 5:14 p.m.
Pharmacoeconomic Study Compares Total Hospital Costs of AmBisome® to Abelcet® for Empirical Treatment of Patients with Febrile Neutropenia
Printer Friendly Version 
August 02, 2000 - 5:08 p.m.
Roche Submits Tamiflu for Regulatory Approval in Japan; First Oral Neuraminidase Inhibitor for the Treatment and Prevention of Influenza
Printer Friendly Version 
July 27, 2000 - 4:54 p.m.
Second Quarter 2000 Highlights
Printer Friendly Version 
July 27, 2000 - 4:46 p.m.
Gilead Sciences Announces Second Quarter 2000 Financial Results
Printer Friendly Version 
July 14, 2000 - 4:44 p.m.
International AIDS Conference Webcast Attracts Thousands in First Week WEBCAST.AIDS2000.COM
Printer Friendly Version 
July 13, 2000 - 4:42 p.m.
Gilead Sciences Calls for Redemption of Convertible Subordinated Notes
Printer Friendly Version 
July 05, 2000 - 4:33 p.m.
FDA Approves AmBisome® for the Treatment of Cryptococcal Meningitis in AIDS Patients
Printer Friendly Version 
June 26, 2000 - 4:30 p.m.
XIII International Aids Conference to Be Broadcast on World Wide Web WEBCAST.AIDS2000.COM
Printer Friendly Version 
June 16, 2000 - 4:27 p.m.
Roche Seeks to Broaden Tamiflu Treatment Indication with Pediatric Application
Printer Friendly Version 
June 12, 2000 - 4:27 p.m.
Gilead Begins Multinational Phase III Trial of Once-Daily Oral Anti-HIV Drug, Tenofovir Disoproxil Fumarate, in Treatment-Naïve Patients
Printer Friendly Version 
May 26, 2000 - 3:59 p.m.
Roche to Submit Additional Data on Tamiflu for the Treatment of Influenza to the European Regulatory Authorities
Printer Friendly Version 
May 23, 2000 - 3:57 p.m.
Roche Seeks New Tamiflu Indication for the Prevention of Influenza
Printer Friendly Version 
April 27, 2000 - 3:48 p.m.
2000 First Quarter Highlights
Printer Friendly Version 
April 27, 2000 - 3:45 p.m.
Gilead Announces First Quarter 2000 Financial Results
Printer Friendly Version 
April 16, 2000 - 3:42 p.m.
Gilead Sciences Presents 48-Week Phase II Safety and Efficacy Results for Once-Daily Anti-HIV Agent, Tenofovir DF
Printer Friendly Version 
April 11, 2000 - 3:33 p.m.
Gilead Presents Preliminary Clinical Data Describing Activity of Adefovir Dipivoxil Against Lamivudine-Resistant Hepatitis B Virus
Printer Friendly Version 
April 05, 2000 - 3:20 p.m.
Gilead Sciences and EyeTech Pharmaceuticals Announce Exclusive License of Potential New Therapy for Age-Related Macular Degeneration
Printer Friendly Version 
March 20, 2000 - 3:16 p.m.
Canada Approves Antifungal Agent Ambisome®
Printer Friendly Version 
March 07, 2000 - 2:56 p.m.
Gilead and Virco Announce U.S. Collaboration to Promote One of the First Pharmacogenomic Applications for HIV Resistance Tests and Services
Printer Friendly Version 
February 17, 2000 - 2:52 p.m.
Gilead Sciences Announces Changes in Senior Management Team
Printer Friendly Version 
February 10, 2000 - 2:50 p.m.
New AmBisome® Label Includes Claim Of Superior Safety Profile Compared To Abelcet® In Febrile Neutropenic Cancer Patients
Printer Friendly Version 
January 11, 2000 - 2:39 p.m.
Gilead Begins Second Pivotal Phase III Trial of Once Daily Oral Hepatitis B Drug, Adefovir Dipivoxil 10 mg
Printer Friendly Version 
NASDAQ (US Dollar)
$82.62
 Stock is Down 0.02 (0.02%)
Data as of 09/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote